The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)
The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1)
复制标题
DOI：
10.1111/j.1526-4637.2008.00495.x
复制
发表时间：
2009-01-01
期刊：
影响因子：
3.1
通讯作者：
Williamson, Russell
中科院分区：
文献类型：
--
作者：
Bell, Timothy J.;Panchal, Sunil J.;Williamson, Russell
这项基于互联网的多国调查旨在评估接受阿片类药物治疗慢性疼痛并服用泻药的患者中阿片类药物诱导的肠功能障碍（OBD）的患病率、频率、严重程度和影响。共有322名每日口服阿片类药物和泻药的患者完成了45项问卷。在调查时，45%的患者报告每周排便< 3次。阿片类药物引起的最常见的副作用是便秘（81%）和排便困难（58%）。患者认为最令人烦恼的副作用是（按等级排列）便秘、紧张、疲劳、小肠或硬肠运动和失眠。大多数患者每周经历>= 4次问卷中指定的大多数OBD症状。便秘是最常报告为重度的OBD症状。大多数患者报告称，他们的OBD症状对他们的整体生活质量和日常生活活动至少有中度负面影响。三分之一的患者错过了，减少或停止使用阿片类药物，以使其更容易有排便。调查结果证实，OBD经常发生，尽管使用泻药，在个人每天口服阿片类药物治疗慢性疼痛。这些胃肠道症状增加了慢性疼痛患者已经经历的负担，对生活质量产生负面影响，在某些情况下，影响阿片类药物治疗本身。
This multinational, Internet-based survey was designed to assess the prevalence, frequency, severity, and impact of opioid-induced bowel dysfunction (OBD) in patients receiving opioid therapy for chronic pain and taking laxatives.In total, 322 patients taking daily oral opioids and laxatives completed the 45-item questionnaire. At the time of the survey, 45% of patients reported < 3 bowel movements per week. The most prevalent opioid-induced side effects were constipation (81%) and straining to pass a bowel movement (58%). Those side effects considered most bothersome by patients were (in order of rank) constipation, straining, fatigue, small or hard bowel movements, and insomnia.Most of the OBD symptoms specified in the questionnaire were experienced by the majority of patients >= 4 times a week. Constipation was the OBD symptom that was most often reported as severe. Most patients reported that their OBD symptoms had at least a moderate negative impact on their overall quality of life and activities of daily living. A third of patients had missed, decreased or stopped using opioids in order to make it easier to have a bowel movement.The survey findings confirm that OBD occurs frequently, despite the use of laxatives, in individuals taking daily oral opioids for chronic pain. These gastrointestinal symptoms add to the burden already experienced by chronic pain patients, negatively impacting quality of life and, in some cases, affecting opioid treatment itself.